Precigen, Inc. (NASDAQ:PGEN) Receives $7.00 Consensus Target Price from Analysts

Precigen, Inc. (NASDAQ:PGEN) has received a consensus recommendation of “Moderate Buy” from the five analysts that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $7.00.

Separately, HC Wainwright restated a “buy” rating and issued a $4.00 price objective on shares of Precigen in a research note on Friday, November 15th.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Traphagen Investment Advisors LLC acquired a new position in Precigen during the 3rd quarter valued at $29,000. Stifel Financial Corp increased its holdings in shares of Precigen by 94.9% during the 3rd quarter. Stifel Financial Corp now owns 32,200 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 15,680 shares during the period. SG Americas Securities LLC raised its position in shares of Precigen by 44.2% during the third quarter. SG Americas Securities LLC now owns 45,063 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 13,823 shares during the last quarter. AQR Capital Management LLC lifted its stake in shares of Precigen by 56.7% in the second quarter. AQR Capital Management LLC now owns 50,002 shares of the biotechnology company’s stock valued at $79,000 after buying an additional 18,097 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its position in Precigen by 86.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 55,337 shares of the biotechnology company’s stock worth $52,000 after buying an additional 25,681 shares in the last quarter. 33.51% of the stock is currently owned by institutional investors and hedge funds.

Precigen Stock Performance

Shares of PGEN stock opened at $1.12 on Thursday. The stock’s 50 day simple moving average is $0.84 and its 200 day simple moving average is $1.10. Precigen has a twelve month low of $0.65 and a twelve month high of $1.93. The company has a market capitalization of $328.01 million, a price-to-earnings ratio of -2.04 and a beta of 1.71.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.